Department of Oncology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Biosci Trends. 2021 Mar 15;15(1):9-15. doi: 10.5582/bst.2020.01039. Epub 2021 Feb 7.
Gallbladder carcinoma (GBC) is one of the most common malignant tumors in the biliary system, ranking sixth among gastrointestinal malignancies. In addition, the incidence of GBC has recently increased in China. GBC metastasizes early and invades adjacent organs such as the liver, making patients with GBC ineligible for radical surgery and giving them a poor prognosis. What is more, GBC is more inclined to develop chemo-resistance, which requires new strategies for clinical intervention. Cancer immunotherapy has made great advances over the past few years, with improved clinical efficacy against multiple malignancies, including GBC. This review summarizes the immunological characteristics of GBC as well as current advances in immunotherapies for GBC in order to provide new insights into future treatment and prevention of GBC.
胆囊癌(GBC)是胆道系统最常见的恶性肿瘤之一,在胃肠道恶性肿瘤中排名第六。此外,近年来中国 GBC 的发病率呈上升趋势。GBC 早期转移并侵犯肝脏等邻近器官,使 GBC 患者不适宜进行根治性手术,预后较差。更重要的是,GBC 更容易产生化疗耐药性,这需要新的临床干预策略。癌症免疫疗法在过去几年取得了重大进展,对包括 GBC 在内的多种恶性肿瘤的临床疗效得到了改善。本综述总结了 GBC 的免疫学特征以及目前 GBC 的免疫治疗进展,以期为未来 GBC 的治疗和预防提供新的思路。